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New concepts and classification of diffuse gliomas in adults

Daumas‐Duport C

*Centre Hopitalier Sainte‐Anne, Paris, France*

The generic category of diffuse gliomas (DG) includes two distinct tumor entities: tumors derived from oligodendrocyte precursor cells -- OPCs (OligoPDTs) versus those derived from stem cells (SCDTs). Oligo PDTs are IDH‐mutated; the tumor cells express the markers of OPCs PDGFRα and β. This category includes most WHO low‐grade DG and comprises two variants: (1) tumors with TP53 mutations; (2) tumors with 1p/19q loss.

SCDTs are IDHwt, and contain CD34+ tumor stem‐like cells (TSC). This category includes most WHO high‐grade DG and includes two variants: (1) malignant glioneuronal tumors (MGNts) that express markers of glial and neuronal lineage; (2) glioblastomas that according to our restricted definition (GBrd) express markers of glial lineage exclusively and presence of necrosis is required for the diagnosis. In our series of patients with a retrospective diagnosis of OligoPDT, MGNT and GBrd, the median age was, respectively, 40, 57 and 65 years (p \< 0.0001), median overall survival (OS) was 12, 1.3, and 0.5 years (p \< 0.0001); OS in OligoPDTs with or without p53 accumulation: 7.7 *vs.* 18.1 years (p \< 0.0001).

The behavior of OligoPDTs and SCDTs is similar to that of adult OPCs from which they derive. OligoPDTs initially grow as isolated tumor cells -- ITCs (50% of the cases at the time of diagnosis) (i) as astrocytes during development and reactive astrocytes in the injured brain, stromal astrocytes induce microangiogenesis and secrete PDGF, which induces the proliferation of OPCs, and block their differentiation. (ii) In contrast to adult OPCs originating in the cortex, those developing in the sub‐ventricular zone (SVZ) migrate long distances within the white matter: on MRI, OligoPDTs with a superficial localization are typically well circumscribed; those located in the white matter show an infiltrative pattern and have a worse prognosis (OS: 18.1 *vs.* 5.4 years), (iii) lactate dehydrogenase (LDH), is not expressed in the oligodendroglial population of the adult brain and in tumor cells of OligoPDTs suggesting that IDH mutation allows OligoPDTs to overcome the silencing of LDH. SCDTs have an autonomous growth and are highly angiogenic. It has been reported that, as their normal counterpart, TSC generate endothelial cells and that the pluripotency of stem‐cells decreases with age: GBrds arise in elderly patients, do not express markers of neuronal lineage and PDGFR‐negative GBrds carry a worse prognosis (OS: 5.9 *vs.* 9.7 months, p = 0.013).
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Frontotemporal dementia

Cairns N

*Washington University School of Medicine, St. Louis, MO, USA*

The last decade has seen both an expansion and transformation in our knowledge of the genetic etiologies and the molecular pathologies associated with frontotemporal lobar degeneration (FTLD), which encompasses a clinically and neuropathologically heterogeneous group of frontotemporal diseases. Increasingly, there is evidence of a genetic, neuropathological and clinical overlap between both FTLD and amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). Most frontotemporal diseases are characterized by the pathological aggregation of misfolded proteins, either in neurons or glial cells, or both. Specific diagnosis of disease within the broad group of frontotemporal diseases now requires immunohistochemistry to determine the molecular pathology, morphology, and distribution of lesions in the neuraxis, and thereby identify the neurodegenerative disease.

About one half of cases with frontotemporal disease are characterized by inclusion bodies containing the transactive response (TAR) DNA‐binding protein of 43 kDa (FTLD‐TDP).This molecular pathology is found in sporadic cases of frontotemporal disease as well as those with autosomal dominant FTLD/ALS with C9orf72, GRN, VCP, or TARDBP gene mutations. The neuropathology of these conditions is generally characterized by ubiquitin/p62 and TDP‐43‐positive neuronal cytoplasmic inclusions (NCIs), neuronal intranuclear inclusions (NIIs), dystrophic neurites (DNs), and glial cytoplasmic inclusions (GCIs), but the distribution and density of lesions may vary between subtypes.

Although mutations in the FUS gene are most frequent in familial ALS, three apparently sporadic diseases have distinct FUS proteinopathy (FTLD‐FUS): neuronal intermediate filament inclusion disease (NIFID), basophilic inclusion body disease (BIBD), and atypical FTLD with ubiquitin‐immunoreactive inclusions (aFTLD‐U).

About one half of cases have abnormal intracellular cytoplasmic accumulations of the microtubule‐associated protein (MAP) tau encoded by MAPT. In the adult brain, there are normally six isoforms of tau, three isoforms contain three microtubule‐binding repeats (3R tau) and three isoforms contain four microtubule‐binding repeats (4R tau).FTLD‐tau includes sporadic diseases: pick disease (3R), corticobasal degeneration (CBD) (4R), progressive supranuclear palsy (PSP) (4R), and others, and familial cases caused by mutations in MAPT.

Recent developments in the molecular pathology and genetics of FTLD now dictate that a minimal panel of pathological investigations is required for correct diagnosis in this group of diseases. Standardization of nomenclature and approach will facilitate better understanding of clinico‐pathologic correlations, provide insights into pathogenesis, and guide the construction and validation of *in vivo* models.
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Protein aggregate myopathies

Goebel H‐H

*Departments of Neuropathology, Johannes Gutenberg University, Mainz, and Charite, Berlin, Germany*

Intra‐ and extracellular protein aggregation is a well‐known principle in neuropathological conditions, e.g. Alzheimer and Parkinson diseases, giant axonal neuropathy and myofibrillar myopathies (MFM). In myopathology, protein aggregation may be part of lesions, such as ragged red fibers or cores, encountered in certain conditions, e.g. distal myopathies, congenital myopathies, and inclusion body myositis, and foremost in myofibrillar myopathies, the true protein aggregates myopathies (PAM). Among these, primary ones, i.e. those with accretion of mutant proteins, e.g. desminopathies, zaspopathies and others may be distinguished from secondary ones where a mutant protein may not be present. The true frequency of secondary MFM/PAM is not precisely known. Together with the mutant protein a multitude of other extralysosomal proteins may accrue. PAM or MFM are late onset distal myopathies of autosomal‐dominant inheritance, in certain forms associated with cardiomyopathy, and protein aggregates, which show granulofilamentous material by electron microscopy in desminopathies and alpha B crystallinopathies and destruction of sarcomeres in all forms of MFM. Frequent rimmed vacuoles tie protein aggregation to autophagy. Recently autosomal‐recessive forms have been described in desminopathy and alpha B crystallinopathy. From these PAM marked by impaired cytosolic degradation, catabolic forms, anabolic forms owing to impaired synthesis and maturation may be distinguished, represented by actin filament aggregation myopathy, a form of nemaline myopathy, and myosin storage/hyaline body myopathy, often affecting young individuals with heterozygous mutations in the respective ACTA1 and MYH7 genes.
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S1: Updates in neurodegenerative diseases

Update in amyotrophic lateral sclerosis: an experience from Japan

Onodera O^1^, Nishizawa M^2^ and Takahashi H^3^

*Departments of* ^*1*^ *Molecular Neuroscience,* ^*2*^ *Neurology, and* ^*3*^ *Pathology, Brain Research Institute, Niigata University, Niigata, Japan*

One of the most interesting things for the unique features in amyotrophic lateral sclerosis (ALS) is that the frequency of the patients with c9FTD/ALS is extremely low in Japanese population. The diseases resulting from a G4C2hexanucleotide repeat expansion in C9ORF72 occurs on a chromosome 9p21 locus are referred to as 'c9FTD/ALS'. The c9FTD/ALS is 27--46% in FALS and 2--8% in SALA in whites. The presence of a risk haplotype suggests that c9FTD/ALS is resulted from a single founder mutation or a risk haplotype descending from a Scandinavian ancestor. In Japanese, the frequencies of c9FTD/ALS are 3.6% in FALS and 0.1% in SALS. The estimated haplotype indicated that these patients also have the risk haplotype identified in whites. Neuropathological findings of an autopsy case with c9FTD/ALS were indistinguishable from those of white patients. In clinical features, the frequency of dementia is low, and none of the familial cases show vertical transmission in Japanese c9FTD/ALS. The molecular link between the C4G2 expansion and TDP‐43 pathology may provide new insight for the mechanism of the sporadic ALS associated with TDP‐43 pathology.
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Progressive supranuclear palsy and corticobasal degeneration

Yoshida M

*Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan*

PSP and CBD are major sporadic 4‐repeat tauopathies. Tufted astrocytes (TAs) in PSP and astrocytic plaques (APs) in CBD have been regarded as the characteristic pathological hallmarks. To better outline the pathological features of each disease and define the astrocytic inclusions, we reviewed 95 PSP cases and 30 CBD cases. The pathological features of PSP are divided into three representative subtypes: typical PSP type, pallido‐nigro‐luysian type (PNL type), and CBD‐like type. CBD is divided into three pathological subtypes: typical CBD type, basal ganglia‐predominant type, and PSP‐like type. TAs are found exclusively in PSP, while APs are exclusive to CBD, regardless of the pathological subtypes, although some morphological variations exist, especially with regard to TAs. The overlap of the pathological distribution of PSP and CBD makes their clinical diagnosis complicated, although the presence of TAs and APs differentiate these two diseases. Immunoelectron microscopic examination using quantum dot nanocrystals revealed filamentous tau accumulation of APs located in the immediate vicinity of the synaptic structures, which suggested synaptic dysfunction by APs. The characteristics of tau accumulation in both neurons and glia suggest a different underlying mechanism with regard to the sites of tau aggregation and fibril formation between PSP and CBD: proximal‐dominant aggregation of TAs and formation of filamentous NFTs in PSP in contrast to the distal‐dominant aggregation of APs and formation of less filamentous pretangles in CBD. The pathological subtypes of PSP and CBD suggest that the clinical phenotypes are in accordance with the pathological distribution and degenerative changes.
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Synucleinopathy: beyond the brain

Woulfe J

*Ottawa Hospital Research Institute and University of Ottawa, Canada*

Concepts regarding the pathogenesis of Parkinson\'s disease (PD) have undergone substantial revision over the past decade. The Braak hypothesis has engendered widespread support for a spatiotemporally dynamic model whereby alpha‐synuclein (AS) aggregation is initiated not in the substantia nigra, or even the central nervous system, but in the peripheral nervous system from which it "spreads" over time to ultimately involve multiple CNS loci. Initial AS aggregation may be induced by some yet‐to‐be identified environmentally derived toxin or microbial pathogen. This novel model has crucial pathogenetic, diagnostic, and therapeutic implications. The olfactory mucosa and the enteric nervous system (ENS) have been specifically implicated as initial sites of AS aggregation. Within the latter, there appears to be a rostrocaudal gradient of decreasing Lewy pathology, suggesting differential vulnerability of distinct levels of the gastrointestinal tract to AS aggregation. Our studies of the topographical distribution of AS in the ENS of neurologically intact humans have revealed that the mucosal plexus of the vermiform appendix is particularly enriched in AS. This, combined with its dense innervation from neurons in the dorsal vagal complex, one of the first CNS sites to be affected by Lewy pathology, render the appendiceal ENS an attractive candidate as a locus for initial AS aggregation. The status of the appendix as an "immune organ" has further pathogenetic implications as there is increasing support for a role for immune mechanisms in PD pathophysiology. In this context, a hypothesis regarding a possible role for Epstein--Barr virus‐induced autoimmunity in PD pathogenesis will be discussed.
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Characterization of globular glial tauopathies

Kovacs G

*Institute of Neurology, Medical University of Vienna, Vienna, Austria*

Widespread presence of globular glial inclusions (GGIs) characterizes a group of 4‐repeat (4R) tauopathies. Tau immunohistochemistry reveals 4R immunoreactive globular oligodendroglial and astrocytic inclusions. The oligodendroglial inclusions are Gallyas positive; however, the atsroglial inclusions are predominantly negative for Gallyas silver staining. The oligodendroglial tau‐positive globular inclusions are reminiscent of the alpha‐synuclein positive oligodendroglial cytoplasmic inclusions seen in multiple system atrophy. Presence of GGIs associates with a range of clinical presentations, which correlate with the severity and distribution of underlying tau pathology and neurodegeneration. The diverse clinicopathological presentations and GGIs have been described in the literature using various terminologies. A group of neuropathologists formed a consensus on terminology to classify these cases. We agreed that GGIs were present in all the cases reviewed and that the morphology of globular astrocytic inclusions was different to tufted‐astrocyte type inclusions. The different morphological subtypes are likely to represent a spectrum of a distinct disease entity. The term globular glial tauopathy (GGT) was proposed. Three major types were distinguished. Type I cases typically present with frontotemporal dementia, type II cases are characterized by pyramidal features reflecting corticospinal tract degeneration and type III cases can present with a combination of frontotemporal dementia and motor neuron disease with or without extrapyramidal symptoms. Significant degeneration of the white matter is a feature of all GGT subtypes. Improved detection and classification of GGTs helps future studies on tauopathies.

**Acknowledgements**: Participants of the consensus study: Zeshan Ahmed (London, UK), Eileen Bigio (Chicago, USA), Herbert Budka (Vienna, Austria), Dennis W. Dickson (Jacksonville, USA), Isidro Ferrer (Barcelona, Spain), Bernardino Ghetti (Indianapolis, USA), Giorgio Giaccone (Milano, Italy), Kimmo J. Hatanpaa (Dallas, TX, USA), Janice L. Holton (London, UK), Keith A. Josephs (Rochester, MN, USA), James Powers (Rochester, MN, USA), Salvatore Spina (Indianapolis, USA), Hitoshi Takahashi (Niigata, Japan), Charles L. White III (Dallas, TX, USA), Tamas Revesz (London, UK) and Gabor G. Kovacs (Vienna, Austria). Studies of GGK are partly supported by European Commission\'s 7th Framework Programme under GA No 278486, "DEVELAGE."
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Advances in understanding the neuropathology of multiple system atrophy

Holton J

*UCL Institute of Neurology, UK*

Multiple system atrophy (MSA) is a sporadic adult onset neurodegenerative disease with clinical features including parkinsonism, cerebellar ataxia and autonomic failure. Neuropathological examination shows regional neuronal loss and gliosis with widespread oligodendroglia α‐synuclein immunoreactive glial cytoplasmic inclusions (GCIs), which are considered to be the hallmark of MSA. α‐Synuclein immunoreactive inclusions are also found in neurons and MSA is regarded as a member of the group of α‐synucleinopathies that also includes idiopathic Parkinson\'s disease and dementia with Lewy bodies. The pattern of regional neuronal loss has given rise to the concept of pathological sub‐types of MSA and the prevalence of these sub‐types has been shown to vary between different ethnic populations. GCIs are considered to play a key role in the pathogenesis of MSA as their density in affected brain regions correlates with neuronal loss and disease duration. To date there is limited understanding of the mechanisms leading to GCI formation and this is a focus of current research. In this presentation, the neuropathological features of MSA will be described and current insights into the disease pathogenesis will be discussed.
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S2: Microvascular neuropathology

Introduction and classification of small vessel disease

De Girolami U

*Department of Pathology (Neuropathology Laboratory) Brigham and Women\'s Hospital; Harvard Medical School, Boston, MA, USA; and Department of Pathology (Neuropathology Laboratory) Hôpital Lariboisère, University of Paris VII, Paris, France*

Central nervous system (CNS) small vessel disease is an arbitrary subdivision that separates those groups of disorders that affect the nervous system from injury to vessels outside the parenchyma of the brain, i.e. large extra cranial vessels that supply the nervous system and intracranial vessels within the subarachnoid space, from those that penetrate the parenchyma of the brain, i.e. typically arterioles, venules and the components of the microcirculation. This operational definition serves to distinguish major pathophysiological mechanisms of stroke and corresponding clinical syndromes that differ greatly between the two groups.

Three generalizations apply to most forms of CNS small vessel disease -- these are disorders that affect multiple vessels throughout the neuraxis; a broad range of abnormalities accompanies the vascular injury, be it inflammatory, or predominantly non‐inflammatory; the vascular lesions are associated either with focal hemorrhage or thrombosis, with corresponding parenchymal brain injury. In some, the principal clinical manifestations are those of focal neurological deficits referable to the anatomic region involved, whereas in others, syndromes of dementia (with or without associated degenerative disease), or encephalopathies, predominate. The armamentarium of new radiological imaging methods has enhanced awareness of these important causes of neurological morbidity. Some of these affect predominantly or exclusively the CNS, whereas others are systemic vascular disorders that involve the brain and spinal cord along with other organ systems.

For purposes of classification, and conceptually, these are disorders of the "microcirculation" and small blood vessels in general. The so‐called "small arteries" or arterioles include perforators with diameters from 40 to 400 μm. Some emerge from the leptomeningeal arteries, enter the brain parenchyma from the surface of the brain, and extend within to a variable depth, some reaching the deep white matter as medullary branches. Other perforators enter the brain at the base (supplying the basal ganglia and thalamus), and yet others irrigate the brainstem arising from long and short circumferential branches. For the most part, these are end‐arteries with limited collateral anastomoses until the capillary network is reached.

The classification below is offered as a framework for the understanding of CNS small vessel disease: Systemic diseases with CNS involvementAtherosclerosis, diabetes, hypertension -- lacunar infarctionCerebrovascular complications of hematologic disorders -- hemorrhage/infarctionCoagulopathies and occlusive disease, e.g. hyperviscosity syndromes, cryoglobulinemia, TTP, DICHemorrhagic diatheses, e.g. drug‐induced, myeloproliferativeArteriopathic leukoencephalopathy, i.e. Binswanger diseasePrimarily "inflammatory" diseases with systemic involvementInfectious: e.g. fungal (Aspergillus), bacterial, (TB), viral (CMV)Non‐infectiousAssociated with "connective tissue diseases"Polyarteritis nodosaHypersensitivity angiitis (Churg and Strauss)Systemic lupus erythematosusSjögren syndromeWegner\'s granulomatosisAssociated mainly with systemic dermatologic and mucocutaneous syndromesBehcet\'s diseaseSneddon syndromeKöhlmeier‐Degos diseaseCombining ocular and CNS manifestations, e.g. Eales' diseaseNon‐infectious (idiopathic) selectively (or predominantly) CNS small blood vesselsInflammatoryPrimary CNS granulomatous angiitis (with or without amyloid angiopathy)CNS "Autoimmune Vasculitis" in children or adultsSubacute diencephalic angioencephalopathy (possibly related to AV fistulas)Non‐inflammatoryHereditary and non‐hereditary amyloid angiopathyCADASILOtherSystemic mitochondrial disorders affecting CNS blood vessels, e.g. MELASSystemic vasculopathy associated with cancer

For this mini‐symposium, we have selected only a few topics for in‐depth discussion: Introduction to symposium -- basic concepts and classification (De Girolami)Neuroradiologic considerations (Gasparetto)Hereditary diseases of small vessels: Genetics (Tournier‐Lasserve)Hereditary diseases of small vessels: Pathology (Gray)
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Neuro‐radiologic considerations

Gasparetto E

*Universidade Federal do Rio de Janeiro, Departamento de Radiologia, Curso de Pós Graduação Em Medicina Radiologia, Brazil*

In this presentation, we will discuss the most common neuroimaging findings in patients with microvascular pathology. First, we will describe the imaging patterns of microvascular pathology in each magnetic resonance imaging sequence (i.e. T1‐WI, T2‐WI, FLAIR, etc.). Then, we will discuss the differential diagnosis that has to be considered when reading cases that present a "microvascular pathology" imaging pattern. Finally, we will assess the role of the advanced magnetic resonance imaging techniques in the evaluation of patients with microvascular pathology.
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Hereditary diseases of small vessels

Gray F, Tournier‐Lasserve E

*APHP‐Hôpital Lariboisière and Université Paris 7, Paris, France*

Neuropathological data are available only in a few cases of non‐amyloid hereditary diseases of CSV and are occasionally diagnostic.

CADASIL is the prototype of dominant hereditary diseases of CSV. Since the initial description (Baudrimont *et al*. *Stroke* 1993), its neuropathology has been established by numerous reports. Changes in CSV are diffuse and include specific alterations: granular basophilic deposits presenting at e.m. as granular osmiophilic material "GOM" and accumulation of the extracellular domain of Notch 3(ECDN3), which can be identified by immmunohistochemistry (Joutel *et al*., *J Clin Invest* 2000). These diagnostic changes are systemic and can be observed on skin biopsies. Parenchymal brain changes are considered the consequence of ischemia due to vascular stenosis, which is a feature of CADASIL. Subcortical lacunar infarcts and arteriopathic leukoencephalopathy are characteristics of the disease and included in the eponym. Frequent, less classical changes: status cribrosus and involvement of the cerebral cortex, which may result from different mechanisms, will also be discussed.

In the other dominant hereditary diseases of CSV, neuropathological data are rare and less specific.

Retinal vasculopathy with cerebral leukodystrophy is characterized by involvement of SV of the brain and retina. Distinctive multilaminated vascular basement membranes in systemic organs have been found at e.m. However, neuropathological studies are few and non‐specific.

COL 4A1 and COL 4A2 mutations cause systemic small vessel disease. Involvement of the vascular basal membrane in systemic organs has been shown at e.m. but neuropathological study has only been performed in fetuses. It showed cavitary necrotic lesion (porencephaly) and old and recent hemorrhages with abnormalities of small vessel walls.

Idiopathic basal ganglia calcification or Fahr disease is a common incidental neuroimaging or post mortem finding. In some cases, it has been linked to mutations in PDGFRB and in PDGFB and experimental studies suggest that the calcium deposition depends on the loss of endothelial PDGF‐B and correlates with the degree of pericyte and blood‐brain barrier deficiency.

Signal transducer and activator of transcription 3 (STAT3) deficiency is a rare primary immunodeficiency referred to as an autosomal dominant hyper‐IgE syndrome. Recently, vascular abnormalities in heart and brains have been described radiologically. Postmortem examination of a patient who died from ruptured basilar artery aneurysm also showed vascular leukoencephalopathy and abnormalities of CSV likely to result from connective tissue disease.

In a single case of hereditary extensive vascular leukoencephalopathy (HEVL) mapping to chromosome 20q13, neuropathological study showed very specific changes of small terminal arterioles and vasa vasorum, more severe in the cortico‐subcortical areas, basal ganglia, and subependymal regions.

In Swedish hereditary multi‐infarct dementia as in pontine autosomal dominant microangiopathy and leukoencephalopathy (PADMAL), the gene mutation has not been identified. Neuropathological changes are comparable and include multiple lacunar infarcts with severe involvement of the pons. CSV changes include concentric intimal proliferation with hyperelastosis and atrophy of the tunica media in the absence of GOM or ECDN3 deposits.

Recessive hereditary diseases of CSV include CARASIL in which the gene mutation has been identified and neuropathological studies have revealed variable, usually non‐specific, changes of CSV, and leukoencephalopathy, cerebral calcifications and cysts (LCC) the responsible gene mutation of which is not identified but the hereditary character of which is likely given its very suggestive pathology and a notion of consanguinity in some families.
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S3: Recent advances in viral neuroinfection

Neuropathogenesis of enterovirus 71 infection

Wong KT^1^ and Ong KC^2^

^*1*^ *Departments of Pathology and* ^*2*^ *Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia*

Enterovirus 71 (EV71) (family Picornaviridae, genus Human Enterovirus A) belongs to a large group of enteroviruses that also includes the poliovirus. It usually causes mild paediatric hand, foot and mouth disease, manifesting as skin rashes or vesicles in these classical sites. More rarely, complications such as meningitis, acute flaccid paralysis, transverse myelitis and encephalomyelitis may occur. Huge outbreaks of EV71 infection with significant central nervous system (CNS) complications in the Asia‐Pacific region and beyond have become major public health concerns since anti‐viral drugs and vaccines are not yet available. Autopsy studies of fatal encephalomyelitis showed a stereotyped topographic distribution of inflammation, viral infection and destruction of neurons mainly in the spinal cord, brainstem, hypothalamus and cerebellar dentate nucleus with minimal inflammation in the cerebral hemisphere, including the motor area. Entry into the CNS is believed to be via a retrograde peripheral motor nerve route while spread within the CNS may involve other neuronal pathways. Recent evidence suggests that viral replication could occur in the tonsillar crypt epithelium, thus facilitating oral and faecal viral shedding. The tonsil may also be a portal for viral entry into the body. Presumably this is followed by viral replication in other extra‐CNS sites (e.g. skin) and/or viraemia, leading to neuroinvasion in susceptible patients. A hypothesis for EV71 transmission in the CNS will be discussed and compared with poliovirus and Japanese encephalitis virus. The role of the Scavenger Receptor B2 receptor in EV71 neurotropism will be reviewed.
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New infections like the expanding JCV neuropathology

Budka H

*Institute of Neuropathology, University Hospital Zurich, Switzerland*

Recent years have seen the emergence of new viral threats like SARS or MERS coronaviruses, Ebola, dengue, West Nile fever, avian flu, or Hanta, Nipah or Hendra. Most of these infections potentially affect the nervous system and thus are of relevance for neuropathology. However, even hitherto well‐known viruses may change their host spectrum, adapt to changed environments, or change their tropism, leading to new and unrecognized diseases or therapy‐related complications.

One paramount example is the JC polyomavirus (JCV), the causative agent of progressive multifocal leukoencephalopathy (PML) known since 1971. Despite high seroprevalence, JCV has been pathogenic only in immune compromised conditions including AIDS. More recently, PML has emerged as rare but important complication of MS therapy with monoclonal antibodies like natalizumab or rituximab. Moreover, efficient therapy of the underlying immune deficiency, e.g. by HAART in AIDS, may result in the immune reconstitution inflammatory syndrome (IRIS) that converts PML into a fulminant inflammatory disease. Finally, the spectrum of JCV tropism has expanded to meninges, cortical neurons and cerebellar granule cells, giving rise to new diseases of JCV meningitis/encephalopathy or JCV granule cell neuronopathy (JCV‐GCN). The neuropathological and immune basis of the first case of JCV‐GCN after natalizumab treatment, complicated by IRIS, is discussed.
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Rabies encephalitis

Shuangshoti S^1,2^, Sangkara W^3^, Laothtamatas J^3^, Jittmittraphap A^2^, Tepsumethanon V^4^, Wacharapluesadee S^2,5^, Hemachudha T^2,5^

^*1*^ *Department of Pathology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand;* ^*2*^ *WHO Collaborating Center for Research and Training on Viral Zoonoses, Bangkok, Thailand;* ^*3*^ *Department of Radiology, Ramathibodi Hospital Mahidol University, Bangkok, Thailand;* ^*4*^ *Queen Saovabha Memorial Institute, Bangkok, Thailand;* ^*5*^ *Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*

The pathogenesis of furious and paralytic rabies remains to be elucidated. Previous studies in human failed to identify differences between the two clinical forms, and this could be due to the methodology and/or examination late in the disease course. To observe early changes, diffusion tensor imaging (DTI) technique was used to assess blood brain barrier (BBB) (mean diffusivity, MD) and tract integrity (fractional anisotropy, FA) of rabid dogs. Preserved BBB was noted in both clinical forms, whereas cytotoxic edema was more pronounced in the paralytic rabies. Impaired FA (disrupted neural tract integrity) was found at the brainstem of paralytic dogs. At postmortem, more rabies viral antigen was detected in the furious as compared to paralytic rabies in many of the central nervous system regions. Caudal‐rostral polarity of rabies viral antigen as observed in both clinical forms, in order from greatest to least: spinal cord, brainstem, cerebellum, midline structures, hippocampus, and cerebrum. Viral RNA level was significantly higher in the cerebral cortex, thalamus, and brainstem of dogs with the furious sign. Of particular interest, a striking inflammatory response was detected in the brainstem of paralytic rabies, and this finding correlated well with the altered neural tract integrity and presence of interleukin‐1β and interferon‐γ mRNAs. Disruption of axoplasmic flow by inflammation in the brainstem could potentially retard viral propagation toward the cerebral hemispheres in the case of paralytic rabies, and explain the longer survival period as compared to the furious counterpart.
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Recent findings in neuropathology and neuroradiology of HIV infection

Pittella JEH^1^, dos Santos AC^2^, Simão GN^2^ and Neder L^1^

^*1*^ *Department of Pathology,* ^*2*^ *Radiology Division, Internal Medicine Department, Ribeirão Preto School of Medicine, University of Sao Paulo, Brazil*

In order to achieve the changes related to the regular use of the highly active antiretroviral therapy (HAART), we present the spectrum of the neuropathology findings and the correlation between the CNS MRI scans prior to patients' death and the neuropathological features as well as clinic‐laboratorial data from 70 HIV‐infected adult patients, who were followed at Hospital of Clinics of Ribeirão Preto School of Medicine at University of São Paulo. After autopsy, the brains were fixed in 10% formalin for 2 weeks before cutting and representative areas were sampled according to standard protocol. Demographic, clinical, and laboratory data were recorded from clinical charts. As expected, we found a high rate of irregular use of HAART in patients with clinical deterioration, but the use of HAART, even irregularly, was associated with longer patient survival. However, the frequency of CNS infections and/or cognitive impairment was significantly higher in patients who did not receive any HAART therapy. The most frequent CNS opportunistic agents were *T. gondii*, *C. neoformans* (leptomeningeal dissemination, cryptococcomas and basal ganglia "soap bubbles"), Mycobacterium tuberculosis (leptomeningitis) and cytomegalovirus. The most relevant finding was more than one infectious agent in the same brain or cases with multiple old lesions ("infection scars"). Interestingly, we had some cases with concomitant primary CNS lymphoma, HIV‐leukoencephalopathy, PML and nodular encephalitis. Despite some caveats, the best correlation between MRI and histopathology was seen in foci of coagulative necrosis in toxoplasmosis, with eccentric target sign and T1 hyperintensity on lesions with calcification.
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The emerging viral encephalitidies

Wiley C

*University of Pittsburgh, USA*

Despite major advances in the control of infectious diseases, new pathogen/human host associations continue to emerge. Historically, many of these emergent infections were the result of disruption of biosphere equilibriums with introduction of new pathogens into previously unexposed populations. For unknown reasons, infection of the brain has suffered a disproportionate share of these diseases. In addition to ecological disruptions, man has chosen to deliberately manipulate pathogens to achieve lethal destruction of his fellow man. These bioterrorism efforts have led to introduction of well‐characterized agents through novel routes (e.g. aerosol dispersion) circumventing normally protective immunological responses. To protect himself from infectious agents, man has also attempted to created vaccines to obviate severe disease associated with initial exposure. While on the whole, these vaccines have been highly successful means of conferring protective immunity, they do not provide as robust an immune protection as a natural infection. Unfortunately, protection from lethal systemic disease has not been universally associated with protection from lethal encephalitis. Finally, the sheer size of the human population and its associated biome have resulted in the emergence of virulent pathogenic strains from ubiquitous less pathogenic organisms. Again, for unclear reasons, many of these new pathogens exact a profound toll on the human brain.
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MicroRNA regulation of progressive multifocal leukoencephalopathy

Struckhoff AP^1^ and Del Valle L^1,2^

^*1*^ *Stanley S. Scott Cancer Center, Louisiana State University Health, New Orleans, LA, USA;* ^*2*^ *Department of Pathology, Louisiana State University School of Medicine, New Orleans, LA, USA*

Progressive Multifocal Leukoencephalopathy (PML) is a fatal disease of the CNS, result of the opportunistic infection by the human neurotropic JC virus (JCV), and frequently seen in immunocompromised patients. PML is characterized by extensive demyelination of the subcortical white matter caused by the lytic destruction of oligodendrocytes. There is no effective treatment for PML and the median survival rarely surpasses 6 months. A growing concern is the development of PML as side effect of immunomodulatory therapy in the treatment of numerous autoimmune diseases.

MicroRNAs are small (∼22 nucleotides), non‐coding RNA molecules that are present in the genomes of almost every organism and influence biological processes by regulating expression of their target gene(s). It is predicted that approximately 50% of all genes are regulated by microRNAs making them important regulators of most physiological processes, including apoptosis, differentiation, and immune regulation; as well as many pathophysiological processes such as inflammatory disease, neurodegeneration, and cancer.

Preliminary data of the first high‐throughput microRNA profile of PML revealed 54 microRNAs up‐regulated and 17 microRNAs down‐regulated by a greater than 2‐fold difference. Target gene and gene ontology (GO) analysis suggests that among the pathways targeted by these microRNAs, there in an enrichment in pathways involved in regulation of apoptosis, nucleotide metabolism, NF‐κB signaling, and cytoskeletal organization. We corroborated the up‐regulation of MCDC2, an apoptotic regulator. In addition, we have found two virally generated microRNAs, encoded in the c‐terminal of the large T‐Antigen gene, which provide JCV with innate immune evasion capabilities and help its replication cycle.
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S4: Peripheral neuropathies

Introduction: the procedures and utility of nerve biopsies nowadays

Vallat JM

*National Referral Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital, Limoges, France*

The indications for nerve biopsy (NB) have declined over the last 20 years, due to progress in molecular biology for diagnosing genetic neuropathies (PN) and to the increasing use of skin biopsy. The latter is mainly employed to evaluate small‐fiber PN, and it rarely discloses the etiology of a PN.

Usually, NB concerns mostly either the sural or the superficial peroneal nerve, which is combined with removal of specimens from the peroneus brevis muscle. The diagnosis of vasculitic lesions can be readily established on nerve paraffin‐embedded fragments, although in some cases, characteristic lesions are only visible on muscle specimens.

Other nerve specimens are fixed in buffered glutaraldehyde and prepared for semi‐thin sections, while frozen specimens are prepared for immunofluorescence study. Electron microscopy (EM) is of great value in some cases of "atypical" chronic inflammatory demyelinating polyneuropathies (CIDP), when the clinical and electrophysiological European Federation of Neurological Societies/Peripheral Nerve Society criteria are absent and in PN associated to a monoclonal gammopathy (MG). In these dysimmune neuropathies, treatments according to the mechanisms of lesions of the nerve parenchyma are quite efficient.

With respect to genetic PN, more than 60 genes may be involved; if the most frequent gene mutations have not been detected, detailed pathological analysis of the nerve can orient the search for mutations in specific genes.

ImmunoEM may be very useful in some cases of MG.

So, NB is still of great value provided that it is performed and examined in a laboratory specialized in the field of nerve pathology.
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Skin biopsy in neuropathology: indications, techniques and results

Sommer C

*University of Würzburg, Germany*

Skin biopsy has become a widely used tool to investigate small caliber sensory in peripheral neuropathies. Different techniques for tissue processing and nerve fiber evaluation have been employed and validated. The quantification of intraepidermal innervation can be useful to detect a pathological correlate for otherwise unexplained burning pain in the toes or feet, i.e. small fiber neuropathy. Normative values for different body areas have been established. For diagnostic purposes in peripheral neuropathies, one biopsy is performed at the distal leg (10 cm above the lateral malleolus) and a further one at the proximal thigh (20 cm below the iliac spine) in order to gain information on whether the disease is length dependent. Using appropriate immunohistochemical stains, different nerve fiber populations can be investigated in the skin. Quantification of pilomotor and sudomotor nerves gives information on autonomic nervous system involvement in peripheral neuropathy. Recently, the possibility to sample myelinated fibers and mechanoreceptors, particularly in glabrous skin has extended the application of skin biopsy to questions of myelin pathology. In particular, the new area of nodo‐paranodopathies may benefit from analysis of Ranvier nodes in dermal nerve fibers. Immunostaining for inflammatory cells may help in the diagnosis of vasculitic neuropathy. Skin biopsy being only minimally invasive also lends itself to serial investigation, such that studies on nerve regeneration in skin have been performed. Quality control measures must be followed at all levels to ensure the optimal use of skin biopsies.
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Diagnosis and pathogenesis of neural leprosy

Antunes SLG, Jardim M, Vital RT, Chimelli LMC, da Costa Nery JA, Sales AM and Sarno EN

*Laboratory of Leprosy, Oswaldo Cruz Institute, Rio de Janeiro, Federal University of Rio de Janeiro, Brazil*

Leprosy is a highly prevalent infectious peripheral neuropathy in Brazil, India and Africa, which causes physical disabilities and deformities. It mostly affects skin and the peripheral nervous system among other organs. It can compromise exclusively the peripheral nerves configuring the primary neuritic leprosy without cutaneous lesions. The absence of acid fast bacilli in the nerve biopsy specimens makes diagnosis more difficult as the evidences have then, to be based on nonspecific morphological changes of the nerves, on the detection of *Mycobacterium leprae* DNA in the nerve samples, of serum anti‐phenolic glycolipid and the presence of *M. leprae* antigens in the nerve specimens by immunohistochemistry. A high integration between clinicians, pathologists and laboratory professionals must be achieved in order to increase diagnostic efficiency. In regard of its pathogeny, the participation of metalloproteinases was addressed, showing the capacity of *M. leprae* to induce the mRNA expression and protein synthesis of MMP9 and MMP2 on Schwann cells lineage ST88‐14 *in vitro*. The higher expression of MMP9, MMP2 and tissue inhibitor of metalloproteases found in leprosy affected nerves also corroborated the *in vitro* findings and these elevated expression was associated with the presence of inflammatory infiltrate and fibrosis. Nerve fibrosis is one of the main features of neural leprosy and *M. leprae* induces transdifferentiation of Schwann cells to myofibroblasts a property that can be involved in the intense collagen deposit found in leprosy‐affected nerves. Excessive expression of a fibrogenic cytokine such as CCL2 was detected in leprosy nerves and could contribute to the end‐stage fibrosis.
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Pathological findings in peripheral nerve lymphomas

James P and Dyck B

*Mayo Clinic, USA*

**Introduction:** Neurolymphomatosis (NL) is a rare presentation of lymphoma in peripheral nerves.

**Objective:** To determine the electrophysiological, radiographical, pathological findings and neuropathy pattern in NL.

**Methods:** Retrospective review of NL patients proven by nerve biopsy.

**Results:** 48NL patients were identified (28 primary and 20 secondary NL). The most common presentations were asymmetric, painful radiculoplexus neuropathy (37.5%), polyradiculoneuropathy (23%) and multiple or single mononeuropathy (18%). Primary and secondary NL presented similarly with primary NL having longer symptom duration (10 *vs.* 6 months, p \< 0.001), single disease episode (96% *vs.* 35%, p \< 0.001), disease remission (58% *vs.* 20%, p = 0.056) and lower mortality (25% *vs.* 67%, p = 0.054). 11 of 42 patients had electrophysiology showing demyelination. Nerve biopsies diagnostic of lymphoma were distal cutaneous (sural; 9/11) or proximal targeted fascicular (35/35). MRI was better identifying lymphoma than CT or PET (84% *vs.* 46% *vs.* 58%). The lymphomas were B cell (46/48; only two T cell) with diffuse large B cell most common. Teased fibers showed increased demyelination (19/24), axonal degeneration (18/24) and empty nerve strands (9/24). Endoneurial lymphoma was common (43/48) follow by epineurial (29/33). Pathology of primary and secondary NL were similar with secondary NL having more axonal degeneration (31% *vs.* 7%; p = 0.0005).

**Conclusion:** Peripheral nerve lymphoma (NL) is a multifocal painful neuropathy that causes endoneurial inflammatory demyelination.Primary NL presents as single episodes. Secondary NL presents after remission suggesting that nerve may act as a "safe lymphoma haven" -- most chemotherapeutic agents cannot cross the blood nerve barrier.Primary NL is less severe with longer disease duration, less axonal degeneration and higher survival rates.
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Nerve biopsy may be very useful in some genetic neuropathies

Vallat JM

*National Referral Center for Rare Peripheral Neuropathies, Department of Neurology, University Hospital, Limoges, France*

At the present time, about 60 genes are known to be linked to Charcot‐Marie‐Tooth (CMT) diseases: a careful recording of a possible hereditary transmission and of clinical and electrophysiological data may orientate to look at first, for anomalies of the most frequently involved genes, using classical techniques of molecular biology. Actually, PMP22 duplication or P0, Connexin32 and MFN2mutations will be found in many cases. Then, detailed pathological analysis of the nerve lesions can orientate the search for mutations in specific genes. The various characteristic pathological lesions encountered in CMT diseases according to the mutated gene will be presented and discussed.

If a hereditary sensory neuropathy is suspected, NB is not necessary. Nevertheless, only EM can detect a severe and characteristic involvement of the unmyelinated axons as it is in amyloid neuropathy.

Moreover, morphological patterns suggestive of a hereditary neuropathy may be detected in nerve biopsies from patients with seemingly sporadic neuropathy of unknown etiology. Such disorders as amyloidosis, giant axonal neuropathy, polyglucosan body disease and infantile or juvenile neuroaxonal dystrophy are now rarely diagnosed by a nerve biopsy.

The peripheral nervous system is often involved in various lipidoses: Fabry\'s disease, metachromatic leukodystrophy, adrenoleukodystrophy, etc. Nowadays, a gene mutation has been identified in many of these disorders, so that molecular biology is now firstly considered as a diagnostic procedure.

The use of new‐generation sequencing methods by selecting a great number of gene variants could benefit of combining for each patient not only clinical and electrophysiological data, but also microscopic observations.
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LS1: Recent advances in the neuropathology and neurobiology of epilepsies

The first international consensus classification of hippocampal sclerosis

Blümcke I

*Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany*

Hippocampal sclerosis (HS) has long been recognized as most common structural lesion in patients with temporal lobe epilepsy (TLE), and presents with a broad spectrum of electro‐clinical, structural and molecular pathology findings. In past decades, various attempts have been made to classify specific neuropathology patterns of hippocampal neuronal cell loss and correlate subtypes with postsurgical outcome. A task force from the Diagnostic Methods Commission of the International League against Epilepsy (ILAE) reviewed previous classification schemes and proposed a system based on semi‐quantitative hippocampal cell loss patterns that can be applied in any histopathology laboratory. Inter‐ and intra observer agreement studies reached consensus to classify three types in anatomically well preserved hippocampal specimens (HS ILAE Type I, II or III; details will be presented). Surgical hippocampus specimens obtained from TLE patients may also show normal content of neurons with reactive gliosis only (no‐HS). This first international consensus classification will aid in the characterization of specific clinico‐pathological syndromes, explore variability in imaging and electrophysiology findings, and postsurgical seizure control.
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Developmental tumours and focal cortical dysplasia: improving management by abandoning simplistic views

Palmini A

*Porto Alegre Epilepsy Surgery Program, Neurology and Neurosurgery Services, Hospital São Lucas, Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil*

It is debatable whether developmental tumours (DT) and focal cortical dysplasia (FCD) are part of a neuropathological continuum or represent distinct entities. Because surrounding cortical dyslamination is so frequently associated with DT, this debate impacts upon presurgical evaluation and surgical treatment of refractory partial epilepsies due to DT. The new ILAE classification of FCD recently fuelled this controversy by creating a category in which cortical dyslamination (i.e. FCD type I) is associated with DT, comprising the 'new' category FCD type III. For this to be clinically meaningful, it is important to decide on the epileptogenic relevance of the dysplastic abnormalities (i.e. dyslamination) associated with the DT. More specifically, it is important to determine whether dyslaminated cortex surrounding a DT can generate seizures on its own, or whether it is of low epileptogenic relevance -- and seizures are solely dependent on the DT. The problem is compounded by the fact that intermingled with the dyslamination there are often satellites of the tumour and it is unclear whether persisting seizures following lesionectomies are due to remaining 'dysplasia (i.e. dyslamination)' or subtotal resection of the tumour (i.e. persistence of satellites).

We will present a tailored approach to epilepsy‐related DT, abandoning the simplistic view that all patients should be evaluated with intracranial EEG electrodes, on the rationale that the seizure onset zone is otherwise uncertain. Taking into consideration clinical, scalp EEG and imaging features, we will report the Porto Alegre series of epilepsy‐related DT operated under acute ECoG guidance. We will make the point that decades of experience with costly and risky intracranial EEG evaluations do allow more objective, successful approaches.
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Prevention of epileptogenesis and neoepileptogenesis in temporal lobe epilepsy: are we getting closer?

Leite JP

*Departamento de Neurologia, Psiquiatria e Psicologia Médica, Universidade de São Paulo -- Campus Ribeirão Preto, São Paulo, Brazil*

Temporal lobe epilepsy with hippocampal sclerosis is the most common type of intractable partial epilepsy. Surgical removal of mesial temporal structures may lead seizure freedom. However, surgery may fail and a substantial number of patients will continue to be refractory to drug treatment. Therefore, prevention of epileptogenesis after a primary brain insult could be an inventive method to reduce pharmacoresistant epilepsy. Here, we will address the current knowledge on the underlying mechanisms involved in epileptogenesis, and on the potential novel treatments that may lead to prevention of intractable epilepsy. So far, all clinical and the vast majority of experimental studies have fail to truly prevent (cure) epilepsy after a brain injury. Nevertheless, some experimental studies have shown that prophylactic treatment with different compounds may lead to diminished brain damage, reduction of frequency and severity of spontaneous seizures and reduction of behavioral and cognitive deficits. Such preventive approaches have diverse underlying mechanisms of action and include antiepileptic drugs, neuropeptides, immunosuppressant and anti‐inflammatory agents, neurotrophic factors, nucleosides and even proconvulsant drugs.

One of the reasons that may explain the relatively low success of such therapeutic approaches is our limited knowledge of the pathophysiology of epileptogenesis after a brain insult such as status epilepticus or traumatic brain injury. The choice of animal model to test these compounds also seems relevant and a rational approach with combination of models that allow screening large number of drugs with more complex and time‐consuming models such as kindling or animals with spontaneous seizures should be encouraged.

Financial support: FAPESP, CNPq and CAPES.
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Focal cortical dysplasia associated with perinatal ischemic injury

Honavar M

*Hospital Pedro Hispano, Portugal*

Cortical dysplasia frequently presents with epilepsy resistant to drug therapy, and when localized becomes a candidate for treatment by surgical resection. The consensus classification of focal cortical dysplasia (FCD) by the ILAE task force in 2011, rightly proposed separation of cortical abnormalities associated with other pathological lesions into a separate category, and FCD associated with lesions acquired during early life, other than with vascular malformations, has been designated FCD Type IIId.

Epilepsy surgery resections for lesions resulting from perinatal ischemic injury range from small cortical and larger lobar resections to hemispherectomies, and the principal abnormalities found in these specimens consist of porencephaly with microgyri and ulegyria. The latter two are also seen as isolated lesions. The adjacent cortex may be thin and attenuated with disorganized architecture and absence of lamination, or represented by nodules of gray matter. The cortex may appear thick and marbled, with aberrant myelinated axons running vertically up between groups of neurons. In some cases, cortical lamination is maintained, but neurons are reduced in number. Focal microcolumnar arrangement of neurons is often found in cortex adjacent to the main lesion. Hypertrophic neurons are frequently found in the microgyri and the surviving crowns of ulegyria and may be found in the better preserved cortex further away.

Recognition of these changes as secondary to the perinatal insult is not difficult in large resections with an appropriate clinical history. It may be more challenging in resections of small lesions in older subjects with neuroimaging "suggestive of cortical dysplasia."
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LS2: Angiogenesis and brain tumors

Angiogenesis in high‐grade gliomas: prominent, but promising?

Wesseling P

*Departments of Pathology, VU University Medical Center, Amsterdam, and Radboud University Medical Center, Nijmegen, The Netherlands*

In high‐grade diffuse gliomas, florid, often "glomeruloid" microvascular proliferation and necrosis emerge. In fact, these changes are used as robust histopathological criteria to diagnose high‐grade malignancy in these neoplasms. Also, since it was hypothesized that solid tumors are dependent on angiogenesis for survival and growth, glioblastomas have been considered as good candidates for anti‐angiogenic therapy. Indeed, VEGF inhibition resulted in potent anti‐tumor effects in different glioma xenograft models. Such findings have led to clinical trials in glioblastoma patients with different anti‐angiogenic agents. Follow‐up scans of glioma patients that were treated with the anti‐VEGF antibody bevacizumab often revealed reduced vasogenic brain edema and reduced contrast enhancement of the neoplasms. Unfortunately, two recently published large, prospective and randomized trials (AVAGLIO, RTOG) did not show benefit for overall survival for patients who received bevacizumab as part of their treatment for primary glioblastoma. To those familiar with the histology of glioblastomas this may not come as a surprise. First of all, the efficacy of anti‐angiogenic treatment may be limited because of the diffuse infiltrative character of this neoplasm with many tumor vessels being incorporated rather than newly formed. Furthermore, in areas that do show a prominent angiogenic response the contribution of the (often markedly abnormal!) microvasculature to the perfusion of the tumor tissue may be limited and for sure was not able to prevent necrosis to occur. Smart combinatorial and/or metronomic approaches seem to be necessary for more efficacious (anti‐angiogenic) treatment of high‐grade gliomas.
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Anti‐angiogenesis and hypoxia in gliomas: what have we learned

Zagzag D

*NYU Langone Medical Center, USA*

A critical barrier to progress in the treatment of patients with glioblastomas (GBMs) who receive bevacizumab (Avastin®) combined with chemotherapy is the yet unexplained resistance to anti‐angiogenic therapy. Although an improvement in quality of life and performance status is the subject of debate, these patients have experienced a prolongation of their progression‐free survival, but not overall survival, compared to historical controls, and relief from steroid dependence due to diminished tumor edema. However, most patients eventually relapse and die of their disease, with unprecedented tumor dissemination due to acquired or intrinsic resistance to bevacizumab.

Using clinical specimens, cell culture and animal models of gliomas to investigate these molecular events, we and others found that bevacizumab treatment increased tumor cell invasiveness and expression of hypoxia‐regulated molecules, such as the transcription factor HIF‐1α as well as the CXCR4 and c‐MET receptors at the invasive edges of tumors (Zagzag, 2006, 2008; Esencay, 2010; Lu, 2012). We hypothesize that vascular remodeling triggered by bevacizumab leads to a more hypoxic tumor microenvironment that may promote glioma cell invasion into the normal brain parenchyma, as noted during the development of resistance. Our studies provide novel insight into the hypoxic reprogramming of glioma tumors and their mechanisms of resistance to bevacizumab, and may help in the development of new therapeutic approaches to benefit patients with GBM. In addition to GBM therapy, new applications of bevacizumab to the treatment of neurofibromatosis 2‐associated vestibular schwannomas and radiation‐induced cerebral necrosis have been reported.
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Experience with anti‐angiogenic therapy in clinical practice

Baldotto C

*Instituto Nacional de Câncer, Brazil*

Glioblastoma (GB), a highly aggressive malignant primary brain tumor, is among the most vascularized tumors, and relies upon angiogenesis for growth and histological progression. Angiogenesis in GB, like all solid tumors, is mediated primarily by vascular endothelial growth factor (VEGF), which is also an important vascular permeability factor, and is therefore the primary culprit behind vascular cerebral edema, a major cause of morbidity in brain tumor patients.

Bevacizumab (BV), an anti‐VEGF monoclonal antibody, became the first clinically validated antiangiogenic therapy for recurrent GB. BV demonstrated significant clinical activity in non‐comparative phase II studies used as a single agent or in combination with chemotherapy. Clinical activity was mostly based on reduced need for steroids, impressive radiological responses and promising survival rates.BV introduction into clinical practice brought some challenges, like how to evaluate tumor response, and a wide spectrum of toxicities, such as hypertension, thromboembolism, and especially delayed wound healing and bleeding.

Currently, the clinical benefit of adding BV to first‐line standard therapy is being discussed with the publication of two phase III clinical trials, showing a lack of overall survival benefit and some contrasting results regarding quality of life, despite an improvement in progression‐free survival. Finally, despite some advances, many significant treatment challenges remain. There is an urgent need to validate predictive biomarkers for patient selection and monitoring the efficacy of anti‐VEGF treatment. In addition, more work is needed to better understand the biology of both tumor response to antiangiogenic therapy and the mechanisms of tumor escape.
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WS1: Surgical neuropathology challenges: new and not so new entities

CLIPPERS

Uro‐Coste E and Delisle MB

*Department of Pathology, University Hospital, and INSERM U1037, Toulouse, France*

CLIPPERS, a CNS inflammatory disease, was defined by Pittock *et al*. in 2010 as a steroid‐responsive and steroid‐dependent relapsing‐remitting disease, combining clinical brainstem attacks, characteristic punctate and curvilinear enhancing lesions involving the pons and/or the middle cerebellar peduncles, and the presence of perivascular lymphocytic infiltrates. This mainly T‐CD4 infiltrate had a very low specificity. The role of the neuropathologist is to rule out differential diagnoses, especially vasculitis and lymphoma and to suggest the hypothesis of CLIPPERS in a multi‐disciplinary approach.

Nevertheless, two reported cases of typical CLIPPERS have evolved into primary CNS lymphoma (PCNSL) and one into primary CNS lymphomatoid granulomatosis (PCNS‐LYG). In these three patients, some unusual findings could challenge the diagnosis of CLIPPERS: remnant gadolinium enhancement after steroid therapy, asymmetrical involvement of the brainstem, relapses becoming less sensitive to steroid.

As suggested by Taieb *et al*., CLIPPERS could sometime be a pre lymphoma state, representing an effective host immune response (i.e. sentinel lesion in PCNSL or PCNS‐LYG grade I in LYG) preventing a clonal proliferation of B‐cells. When this immune response becomes too weak, B‐cell lymphoma or PCNS‐LYG grade III could emerge. Pittock *et al*. suggested another hypothesis: CLIPPERS might be an autoimmune disorder triggered by an unknown perivascular antigen. Then in some rare CLIPPERS patients, chronic antigenic stimulation might lead to malignant transformation of B‐cells targeting this antigen.

Finally, CLIPPERS could be a syndrome rather than a single disease, including initial stage of CNS B‐cell lymphoma and LYG.
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N‐methyl‐D‐aspartate (NMDA) encephalitis

Molnar P

*Institute of Pathology, University of Debrecen, Hungary*

The current concept of autoimmunity is based on the presumed balance of self‐reactivity and processing of "foreign" antigens. Abnormal CNS autoimmunity results from an in equilibrium between genes, molecular mimicry and environmental factors. NMDA‐receptor encephalitis was first described in 2007 (Dalmau *et al*., *Ann Neurol*) and since then, a whole host of antibodies against synaptic receptor proteins (Caspr2, LGI‐1, GABA‐B, mGluR5, glycine receptor, etc.) have been revealed. The early reports of NMDA receptor encephalitis have shown the involvement of IgG antibodies against the NR1a subunit of the NMDA receptor. Patients with schizophrenia were reported to have IgG antibodies against NR1a/NR2b (Steiner *et al*., *JAMA Psychiatry* Jan. 2013). Antibodies to NMDARs have been recently described in diseases that had not previously been thought to have an autoimmune component (CJD and HSV encephalitis). The exact pathogenesis of the neuronal damage is as yet to be clarified and much remains to be done to identify any morphological abnormalities, particularly since biopsy and/or autopsy material to be analyzed is scarce. In sight of this recent plethora of reports, it seems useful to review the diagnostic criteria for anti‐NMDAR antibody encephalitis and related morphological observations. The latter partly are our own observations (Barry *et al*., *Br J Psychiatry* 2011). The present review shows that GluN1 IgG antibodies are specific for the syndrome of anti‐NMDAR encephalitis. GluN1 IgM or IgA antibodies may be associated with the other pathologies (Panzer *et al*., *J Neural Transm* 2014).
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IgG4 encephalitis

Lopes B

*University of Virginia Health System, USA*

IgG4‐related disease has evolved from originally being recognized as a form of pancreatitis to encompass diseases involving numerous organs that may occur in isolation, in various combinations, and in the absence of autoimmune pancreatitis.

In the CNS, IgG4‐related disease has been described affecting the pituitary gland (IgG4‐hypophysitis) and the dura/meninges (IgG4‐related pachymeningitis). Involvement of the brain parenchyma or spinal cord has not been reported thus far.

IgG4‐related hypertrophic pachymeningitis may account for a large percentage of cases previously considered as idiopathic hypertrophic pachymeningitis, and should be considered in the differential diagnosis of such conditions including infectious diseases, inflammatory disorders, and malignant lymphoproliferative neoplasms.

A recent review of the literature (PMID: 24733677) has reported a total of 33 cases with histologically confirmed IgG4‐related pachymeningitis. The majority of the patients were men in the 6th decade of life and the most clinical presentation were related to mechanical compression of either vascular or nerve structures including headaches, cranial nerve palsies and vision problems.

The characteristic histopathological features of IgG4‐related diseases are a rich lymphoplasmacytic infiltration of IgG4‐positive plasma cells, storiform fibrosis, and obliterative phlebitis, all features present in the IgG4‐related pachymeningitis.

The pathogenesis of the IgG4‐related diseases is still not known. Recent data support the concept of an antigen‐driven disease, which involves collaboration between CD4+ T cells and somatically hypermutated oligoclonal IgG4+ B cells.
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Neuroinflammation: A rose by any other name?

Graeber MB and Banati RB

*University of Sydney, Australia*

Over the last decade, the term 'neuroinflammation' has become a widely used portmanteau without generally accepted neurobiological, neuropathological, or neuroimaging tissue correlates. This is problematic in diseases, such as Alzheimer\'s, Parkinson\'s or schizophrenia, where patients have been treated under the broad hypothesis that anti‐inflammatory medication should be of benefit. We have asked the question whether an unbiased, data‐driven *in silico* approach may help to clarify the confusion. Specifically, we have examined whether unsupervised clustering of microarray data obtained from cerebral cortex of Alzheimer\'s, Parkinson\'s and schizophrenia patients would reveal a degree of relatedness between these diseases and recognized inflammatory conditions. Our results provide strong evidence against this hypothesis demonstrating that distinct sets of genes are involved: key characteristics of the inflammatory response are recognizable across different organs at the histophenotypic and the transcriptomic level but are not shared with 'neuroinflammation' (1). Similarly, work using a newly created knockout mouse (Banati *et al*., submitted) indicates that expression of binding sites for a mitochondrial microglial regulator, which is commonly ascribed to activated microglia, can be functionally dissociated from classical microglial activation, calling concepts into question that link activated microglia to non‐autoimmune 'neuroinflammation'. It seems particularly important to determine whether microglial activation in the numerous conditions where it is seen (from sleep deprivation to depression and obesity) relates to synaptic changes and whether the bi‐functionality of complement (inflammatory role in inflammation and synaptic role in healthy and stressed CNS) applies to other molecules originally known from their function in the peripheral immune system.

**Reference**:  1.  Filiou MD, Arefin AS, Moscato P, Graeber MB. 'Neuroinflammation' differs categorically from inflammation: transcriptomes of Alzheimer\'s disease, Parkinson\'s disease, schizophrenia and inflammatory diseases compared. Neurogenetics in press; DOI 10.1007/s10048-014-0409-x.
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Pitfalls in the diagnosis of lymphohistiocytic‐rich intracranial and spinal lesions

Ariza A

*Aurelio Ariza, Department of Pathology, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Spain*

The crosstalk between histiocytes and lymphocytes in chronic inflammation may perpetuate the process and lead to mass formation. Some conditions displaying florid lymphohistiocytic infiltrates pose significant diagnostic pitfalls due to the rarity of their initial or sole presentation in or around the central nervous system (CNS). Such happens with Rosai‐Dorfman disease (RDD), Erdheim‐Chester disease (ECD), and Whipple disease (WD), whose unsuspected diagnoses may be the neuropathologist\'s prerogative to unravel. Intracranial RDD is a deft clinical mimicker of meningioma and may histologically resemble the lymphoplasmacyte‐rich type. Emperipolesis (engulfment of intact lymphocytes by histiocytes) is often difficult to find and typical RDD patterns are commonly obliterated by dense dural fibrosis. CD68 and S100 positivity favors RDD, whereas CD1a negativity excludes Langerhans cell histiocytosis (LCH). ECD, another skillful mimicker of meningioma, is easily overlooked when the characteristic long bone lesions are clinically silent. ECD diagnosis is based on systemic findings and exclusion of RDD and LCH (ECD histiocytes are CD68‐positive but S100‐negative and CD1a‐negative). CNS WD usually manifests itself as lymphocytic encephalitis with numerous PAS‐positive histiocytes, the diagnosis being confirmed by PCR or immunohistochemical demonstration of *Tropheryma whipplei*. Histiocytes are also a prominent feature of LCH (which shows CD68‐negative, S100‐positive, CD1a‐positive dendritic cells), choroid plexus xanthogranuloma (mostly an incidental autopsy finding), and the extremely rare juvenile xanthogranuloma and histiocytic sarcoma. On the other hand, histiocytes are often encountered in the setting of infection, demyelination, infarction, and various tumor types, where they may facilitate or hinder the diagnosis depending on the observer\'s awareness.
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Lymphoma x pre‐lymphomatous lesions

Lopes B

*University of Virginia Health System, USA*

Primary CNS lymphomas (PCNSL) are rare extranodal non‐Hodgkin lymphomas arising in the CNS and/or in the eye in the absence of obvious systemic lymphoma. PCNSL represent about 2.0 percent of all primary CNS tumors (CBTRUS, 2013) and intraocular involvement occurs in 15 to 25% of all patients.

By the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, the terminology PCNSL is restricted to diffuse large B‐cell lymphomas (DLBCL) mostly arising in immunocompetent patients. Lymphomas associated with native or acquired immunodeficiencies, dural lymphomas (mostly low‐grade B‐cell marginal zone type), intravascular B‐cell lymphomas, and T‐cell lymphomas (near less than 5% of the cases) are excluded from this diagnosis and should be considered in their related group.

PCNSL arise in the sixth and seventh decades of life and have a slight male prevalence. The tumors are usually deep within the cerebrum often involving the basal ganglia and periventricular regions. Unlike most primary CNS tumors, they are often multifocal lesions, simulating metastatic tumor.

The great majority of PCNSL are DLBCL genetically expressing germinal center‐associated markers including MUM‐1, BCL‐6, and BCL‐2. However, recent molecular studies have demonstrated that PCNSL have unique gene expression profiling and different than their systemic counterpart.

The diagnosis of PCNSL may be a challenging one in several settings including inadequate sampling of the lesions and, most commonly, effects of corticosteroid treatment prior the brain biopsies. In addition, lymphoid proliferations of uncertain malignancy potential including lymphomatoid granulomatosis may present an extra challenge to the pathologist.
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W2: Epilepsy‐associated brain tumors

Brain tumors with early onset epilepsy: clinical and diagnostic challenges

Cendes F

*Department of Neurology, FCM, UNICAMP, Campinas, SP, Brazil*

Seizures may present as the sole or main manifestation of brain tumors or may occur after other neurological symptoms. Seizures secondary to rapidly growing tumors are usually well controlled by antiepileptic drugs (AEDs) and, therefore, do not require attention by epileptologists. Patients with increased intracranial pressure, or progressive focal neurological signs, are readily referred for brain computed tomography (CT) or magnetic resonance imaging (MRI) scans, which will identify the tumor. Most centers will then move forward to neurosurgical resection with a neuro‐oncologic approach. By contrast, patients with low‐grade glial and glio‐neuronal tumors defined as long‐term epilepsy‐associated brain tumors (LEATs) usually have seizures as the sole manifestation, with onset during early life often refractory to AEDs. LEATs are more common in the mesial temporal lobe and may not be detected by CT. Although MRI is highly sensitive, some LEATs may be missed due to small size and frequent non‐enhancement with gadolinium. Therefore, MRI should include thin coronal T1‐weigheted and fluid attenuated inversion recovery (FLAIR) images to avoid false‐negatives. One challenge is when to indicate surgery in LEAT patients with well‐controlled seizures. By contrast, LEAT patients with non‐controlled seizures have a clear indication of early surgery. Studies have shown better seizure outcome for LEAT patients undergoing tailored resection, including the surrounding epileptogenic tissue, rather than simple lesionectomy. Patients with epilepsy secondary to diffuse gliomas are also challenging because these lesions are highly epileptogenic and frequently cannot be completely resected, leading to frequent refractory seizures that significantly impacts quality of life.
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Long‐term epilepsy‐associated brain tumors (LEAT): how to classify the unclassifiable in your daily routine work‐up?

Blümcke I

*Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany*

Every fourth patient submitted to epilepsy surgery suffers from a brain tumor. These neoplasms present with a large microscopic spectrum of glial or glio‐neuronal tumor subtypes. Gangliogliomas (GG) and dysembryoplastic neuroepithelial tumors (DNT) are the most frequently recognized entities. This particular group of tumors (so called long‐term epilepsy associated brain tumor -- LEAT) differ from most other gliomas (including oligodendrogliomas) by early onset of spontaneous seizures and may be conceptually regarded as developmental tumors to explain their pleomorphic microscopic appearance, which includes biphasic glio‐neuronal variants with or without associated focal cortical dysplasia. However, the broad neuropathologic spectrum and lack of reliable histopathological signatures make LEATs difficult to classify using the WHO classification system of brain tumors. As another consequence from poor agreement in published LEAT series, molecular‐diagnostic data remain ambiguous. We will therefore discuss future approaches for the classification of epileptogenic brain tumors ("epileptomas") in order to promote a comprehensive discussion between neuropathologists, neurooncologists and epileptologists.
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Guidelines for the WHO classification of long‐term epilepsy‐associated brain tumors: is there a current need for revisions?

Perry A

*Department of Pathology, Division of Neuropathology, University of California, San Francisco (UCSF), USA*

Long‐term epilepsy‐associated tumors (LEATs) account for a fourth of surgical specimens obtained for seizure control and include ganglioglioma (GG), dysembryoplastic neuroepithelial tumor (DNT), pleomorphic xanthoastrocytoma (PXA), composite tumors, pilocytic astrocytoma, low‐grade diffuse gliomas, and rarer neoplasms, such as papillary glioneuronal tumor, isomorphic astrocytoma, angiocentric glioma, cortical ependymoma, meningioangiomatosis, meningioma, and extraventricular neurocytoma. They generally share basic clinicopathologic features, including young age of onset, a chronic clinical presentation, low‐grade biology, limited potential for malignant transformation (except for diffuse gliomas and PXA), and a predilection for neocortical and/or mesial temporal lobe involvement. Nevertheless, diagnostic criteria within the current World Health Organization (WHO) scheme are often subjective or vague, leading to low concordance rates among even the most expert neuropathologists. Additionally, non‐classic LEATs and low‐grade glioneuronal tumors are relatively common, particularly in pediatric patients, further complicating the classification of these challenging cases. As such, this lecture will focus on some of the most common diagnostic controversies, rare histologic variants, recent advances, and potentially useful immunohistochemical and molecular markers. Examples of the latter include the strong association of IDH mutations with adult low‐grade diffuse gliomas and the common, but more variable associations of BRAF V600E mutations and CD34‐positive cells with PXA, GG, and DNT. Future efforts by the International League against Epilepsy (ILAE) and the WHO should focus on reproducible, evidence‐based diagnostic criteria in order to create as narrowly defined clinicopathologic and molecular entities as possible, as well as to improve interobserver concordance among neuropathologists.
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Molecular diagnostic findings in long‐term epilepsy‐associated brain tumors: the future for classification of brain tumors

Becker A

*Department of Neuropathology, University of Bonn Medical Center, Germany*

Brain tumors often manifest with epileptic seizures. However, biopsy specimens of patients that undergo neurosurgical removal of circumscribed foci in order to control chronic recurrent pharmacoresistant seizures often reveal tumor entities that are rather rare in general brain tumor series. The spectrum of these 'long‐term epilepsy‐associated neoplasms' comprises highly differentiated glial and glioneuronal tumors that show a benign biological behavior, clinical course and rarely relapse. Several entities are well detectable based on histopathological and immunohistochemical characteristics. A frequent feature of respective neoplasms is given by the co‐incidence with dysplastic lesions, which are in close neighborhood to the tumor itself. The recent advent of new molecular markers including genomic alterations leading to activation of the proto‐oncogene BRAF and impaired function of isocitrate dehydrogenase (IDH1) provide particular valuable new tools in the differential diagnosis of low grade brain tumors and provide intriguing implications to gain further insights the pathogenetic concepts of respective tumor entities. Despite this progress, a number of tumors from chronic epileptic patients show combinations of cyto‐, histological and immunohistochemical characteristics that challenge the current neuropathological classification concept. Attempts are currently ongoing to develop improved classification schemes. An intriguing functional aspect of respective tumors that are often subsumed as 'long‐term epilepsy associated tumors (LEAT)' is their prominent epileptogenicity, which may represent a clinical feature rather indicating than causing the generally benign biological behavior of these neoplasms.
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W3: Prion‐like mechanisms in neurodegenerative disorders

Functional properties of the prion protein in health and widespread implications for disease

Linden R

*Instituto de Biofísica da UFRJ, Rio de Janeiro, Brazil*

Based on multiple interaction partners and pleiotropic signaling properties, we proposed the hypothesis that the prion protein (PrP^C^) is a cell surface scaffold protein that serves as a dynamic platform for the assembly of signaling modules involved in widespread physiological functions. Our recent work is focused on the identification and validation of additional molecular interactions of PrP^C^, as well as on structural evidence for allosteric function of PrP^C^. A phage display screen, together with evidence from PrP^C^‐null mice, implicates several neurotransmitter receptors and/or transporters in PrP^C^‐dependent signaling. Several of these putative ligands have been functionally validated. In turn, biophysical techniques showed that interaction of PrP^C^ with its ligand hop/STI1 entails reciprocal structural remodeling, and strongly suggest allosteric effects that may be involved in the propagation of signals through PrP^C^‐mediated multiprotein complexes. Our current *in silico* studies corroborates this hypothesis. In addition, we tested functional properties and dysfunction of PrP^C^ beyond the nervous system, and found that both peripheral inflammation and behavioral stress modulate the content of PrP^C^ at the plasma membrane of neutrophils, with consequences upon peroxide‐dependent cytotoxicity toward vascular endothelial cells. Our data are consistent with the scaffold hypothesis, which explains the multiple roles of the prion protein in physiology and pathology, and further suggest that PrP^C^ may be relevant for various degenerative/noncommunicable diseases.

Supported by CNPq, FAPERJ, CAPES.
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The role of exosomal secreted Stress Inducible protein 1 in protection against Aβ oligomers toxicity and ischemia

Martins VR^1^, Beraldo FP^2^, Hajj GN^1^, Ostapchenko VG^2^, Prado VF^2^ and Prado MAM^2^

^*1*^ *AC Camargo Cancer Center, São Paulo, Brazil;* ^*2*^ *Robarts Research Institute, Departments of Physiology and Pharmacology, Anatomy and Cell Biology, and Biochemistry, The University of Western Ontario, London, Ontario, Canada*

Stress‐inducible phosphoprotein 1 (STI1) is part of the chaperone machinery, but it also functions as an extracellular ligand for the prion protein (PrP). The physiological relevance of these STI1 activities *in vivo* is unknown. The absence of STI1 is embryonic lethal by E10.5 with mutant mice showing increased caspase‐3 activation, 50% impairment in cellular proliferation, placental disruption and lack of cellular viability. STI1 haploinsufficient mice showed increased vulnerability to ischemic insult. Extracellular STI1 prevented ischemia‐mediated neuronal death in a PrP‐dependent way. In addition, specific binding of AβOs (Aβ oligomers) to PrP is efficiently inhibited by STI. Treatment with STI1 prevented AβO‐induced synaptic loss and neuronal death in cultured neurons and long‐term potentiation inhibition in mouse hippocampal slices. Interestingly, STI1‐haploinsufficient neurons were more sensitive to AβO‐induced cell death and could be rescued by treatment with recombinant STI1. Thus, indicating the essential roles for intracellular and extracellular STI1 in cellular resilience. STI1 is released by astrocytes; however, it lacks a signal peptide and does not follow a classical secretion mechanism. Diverse biochemical and electronic microscopy approaches demonstrated its secretion by exosome‐like vesicles. STI1 partially co‐localized with Rab5 and Rab7 in endosomal compartments, and a dominant‐negative for vacuolar protein sorting 4A (VPS4A), required for formation of multivesicular bodies (MVBs), impaired EV and STI1 release. Flow cytometry and PK digestion demonstrated that STI1 localized to the outer leaflet of EVs, and its association with EVs greatly increased STI1 activity upon PrP‐dependent neuronal signaling. Thus, indicating that the interaction between EVs and neuronal surface components enhances STI1‐PrP signaling preventing neuronal injury by ischemia and AβO toxicity.

Supported by FAPESP, Alzheimers' Association, National Institute for Translational Neuroscience (Brazil), PrioNet‐Canada and Canadian Institutes of Health Research.
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Prion‐like properties for tau

Tolnay M

*Institute of Pathology, Basel University Hospital, Basel, Switzerland*

Filamentous inclusions made of hyperphosphorylated tau are characteristic of numerous human neurodegenerative diseases, including Alzheimer disease (AD), tangle‐only dementia (TD), Pick disease (PiD), argyrophilic grain disease (AGD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). We previously demonstrated that the injection of brain extracts from human mutant P301S tau‐expressing transgenic mice into the brains of mice transgenic for wild‐type human tau (ALZ17) resulted in the assembly of wild‐type human tau into filaments and the spreading of tau inclusions from the injection sites to anatomically connected brain regions. This is consistent with an intercellular transfer of tau aggregates. We have then injected brain extracts from humans with pathologically confirmed AD, TD, PiD, AGD, PSP and CBD into the brains of ALZ17 mice. Silver‐positive inclusions formed in all cases, with the presence of pathological structures reminiscent of AGD, PSP and CBD following the injection of the corresponding human brain extracts. The assembly and spreading of human tau in the ALZ17 brain was independent of Aβ. Similar inclusions also formed after intracerebral injection of brain homogenates from human tauopathies into non‐transgenic mice, and the induced formation of tau aggregates could be propagated between mouse brains. Finally, we have shown that the intraperitoneal injection of brain extracts from symptomatic mice transgenic for human mutant P301S tau into presymptomatic transgenic mice promoted the formation of tau inclusions in brain, albeit less efficiently than following intracerebral injection. Altogether, these findings suggest prion‐like properties for tau.
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Prion‐like features in alpha‐synucleinopathies

Hasegawa M

*Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2‐1‐6 Kamikitazawa, Setagaya‐ku, Tokyo 156‐8506, Japan*

Filamentous alpha‐synuclein (aS) deposition in nerve cells or glial cells is the defining neuropathological feature of Parkinson\'s disease, dementia with Lewy bodies (DLB), and multiple‐system atrophy (MSA). In these so‐called alpha‐synucleinopathies, aS is accumulated in a hyperphosphorylated form with beta‐sheet‐rich, fibrillar structure. During the course of a study of cytotoxicity of aS and tau fibrils, we found that these abnormal fibrils can enter cells and act as seeds for aggregation. I thought that these intracellular abnormal proteins propagate from cell to cell and this spreading can explain the disease progression. Then, we injected synthetic aS fibrils into brains of wild‐type mice and found that these mice developed abundant Lewy body/Lewy neurite‐like pathology. Immunoblot analysis clearly demonstrated that endogenous mouse aS started to accumulate 1∼3 months after inoculation, while injected human aS fibrils degraded in a week. Furthermore, inoculations of Sarkosyl‐insoluble aS from DLB and MSA patients induced similar aS pathology. Inoculation of insoluble aS accumulated in wild‐type mice into other wild‐type mice also induced aS pathology. These results demonstrate that aS fibrils have prion‐like properties and aS pathology spreads throughout the brain by this prion‐like feature. These cellular and mouse models should be useful for evaluating disease‐modifying therapy.
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Propagation of TDP‐43

Brettschneider J

*Oberarzt Neurologie, Universität Ulm, Germany*

Neurodegenerative diseases are increasingly recognized as sharing a unifying pathological principle, i.e. the accumulation of characteristic protein aggregates in neurons and glial cells that are recognized as the hallmarks or diagnostic lesions of these disorders. Converging lines of evidence indicate that disease progression could be driven by a molecular triad of template‐directed protein misfolding, seeded aggregation, and cell‐to‐cell transmission of non‐prion neurodegenerative disease proteins \[2\]. The major component in ubiquitin‐positive neuronal inclusions in sporadic amyotrophic lateral sclerosis (ALS) and a large subset of frontotemporal lobar degeneration (FTLD) is the phosphorylated 43‐kDa TAR DNA‐binding protein (TDP‐43). TDP‐43 is a highly conserved and widely expressed RNA‐binding protein that is a member of the heterogeneous nuclear ribonucleoprotein family of proteins. The defining histopathology of ALS and FTLD‐TDP is the presence of TDP‐43 aggregates in select neurons and glial cells of the central nervous system \[4\]. We recently proposed four stages of TDP‐43 pathology in ALS that suggest a spreading of TDP‐43 directed outwardly from the motor neocortex, spinal cord and brainstem, whereas later stages are characterized by frontal, parietal and anteromedial temporal lobar involvement \[1\]. This sequence of involvement (and the neuro‐axonal loss linked to cellular accumulation of TDP‐43) has recently been corroborated *in vivo* using fiber‐tracking magnetic resonance imaging \[3\]. The frontal dissemination of TDP‐43 pathology could explain why up to 50% of ALS patients develop cognitive deficits related mainly to executive function. We review recent evidence on the dissemination of TDP‐43 from cell culture and mouse model experiments as well as from human tissue studies.
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W4: Updates in muscle disorders

Congenital myopathies

Taratuto AL

*Department of Neuropathology, Institute for Neurological Research, FLENI, Argentina*

Presentation is usually in infancy or early childhood; although late adult onset or clinical heterogeneity among affected members family may also occur. Congenital hypotonia, muscle weakness, facial muscle involvement, ophthalmoplegia, difficulties feeding and respiratory failure may be prominent. CK is low or normal and course may remain stable.

Type 1 predominance/type 1 hypotrophy is typical as are characteristic structural changes, although members of the same family may have only type 1 predominance. Diagnosis may not be conclusive in early biopsies. Inheritance can be autosomal dominant (AD), X‐linked, autosomal recessive (AR) or resulting from dominant *de novo* mutations.

Most frequent entities: Nemaline myopathies, rods visible using Gomori\'s trichrome and EM, of variable clinical severity and age of onset, at least eight genes appear to be involved. NEB mutations, accounting for up to 50% of cases, as well as some core‐rod and distal myopathies. ACTA 1, mostly *de novo* mutations, represent almost half of severe congenital cases.

Core myopathies, with central or eccentric oxidative defects, Z line disruption and absence of mitochondria in the cores, may show severe neonatal presentation or milder forms. AD or AR related to RYR1 gene.

CNM has been linked to at least four genes, XR‐MTM1, DNM2, BIN1 and RYR1, with severe to mild presentation. Morphology findings may orient genetic studies. Congenital fibre type disproportion CFTD shares genes with most other congenital myopathies. Subsequent biopsies may reveal structural changes. Cases still remain with no genetic identification.
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Update on mitochondrial diseases

Oldfors A

*Department of Pathology, University of Gothenburg, Sahlgrenska University Hospital, S‐413 45 Gothenburg, Sweden* <anders.oldfors@gu.se>

Mitochondrial myopathies are caused by defective oxidative phosphorylation and may be caused by mitochondrial DNA (mtDNA) mutations, which can be primary and maternally inherited or secondary to nuclear DNA mutations resulting in reduced mitochondrial DNA copy number or multiple mtDNA deletions. Mitochondrial myopathies may also be caused by nuclear gene mutations that affect the processing of mitochonrial tRNAs or translation of mtDNA encoded polypeptides. In addition, an increasing number of nuclear genes associated with respiratory chain subunits, assembly proteins or other factors of importance for the oxidative phosphorylation have been identified. Clues to correct genetic diagnosis can be obtained by combined morphological, clinical and biochemical investigations. Mitochondrial disorders may rarely present as pure myopathies. Diseases causes by primary mtDNA mutations often present with mitochondrial myopathy with cytochrome c oxidase deficient muscle fibers but important exceptions occur. Mitochondrial myopathy of infancy is sometimes reversible and genetic analysis can be performed to identify such cases. Nuclear DNA mutations with secondary mtDNA alterations such as depletion or multiple deletions usually present with morphological changes in muscle but there are important exceptions. Nuclear DNA mutations causing oxidative phosphorylation disorders present in many cases without evidence of mitochondrial myopathy but there are exceptions e.g. mutations in the iron‐sulphur cluster scaffold protein. Defective phosphatidylcholine biosynthesis causes a type of congenital muscular dystrophy with mega‐mitochondria with structural abnormalities that is not a primary oxidative phosphorylation disorder. In addition, some muscle diseases including various metabolic diseases and age related myopathies may demonstrate mitochondrial changes, which look similar to those present in primary oxidative phosphorylation disorders.

 {#bpa12183_2-sec-0047}

The genetic approach to muscle diseases

Vainzof M

*Human Genome and Stem Cells Research Center, Department of Genetic and Evolutionary Biology, Biosciences Institute, University of Sao Paulo, São Paulo, SP, Brasil*

The neuromuscular disorders are a heterogeneous group of genetic diseases, causing a progressive loss of the motor ability. In the last decade, mutations in several genes have been identified, resulting in the deficiency or loss of function of numerous important proteins. Complementary biochemical and immunohistological analyses have identified these proteins in several compartments of the muscle fiber, including the sarcolemma, extracellular matrix, the sarcomere, muscle cytosol and the nucleus.

Different approaches can be used for the diagnostic, characterization of the diseases, and for the genetic counseling of the family. Both molecular analysis of DNA of candidate genes, and the analysis of the defective protein can be done, according to the clinical hypothesis.

Protein analysis can be used for the differential diagnosis and to direct the search for gene mutations, mainly because there is genetic heterogeneity, and most of the known genes are very large and present wide variability of mutations causing diseases. Protein analysis is also of utmost importance for the elucidation of the physiopathology of each genetic disorder involved. Genotype--phenotype correlation through the analysis of the effect of different mutations on protein expression and on phenotypic variability contributes to the understanding of gene function.

Currently, new methods for wide genome screening are becoming more accessible and able to identify a great variety of mutations and polymorphisms in patients and their families. It is still not possible to evaluate whether this information will help improving diagnosis and genotype/phenotype associations or if it will make the diagnostic process more confusing and complex. However, it will be certainly a giant leap in the genetic analysis of this large group of muscle diseases. Supported by FAPESP‐CEPID, CNPq‐INCT, FINEP, CAPES‐COFECUB.
